Literature DB >> 17697017

Hepatitis C virus (HCV) prevalence, and injecting risk behaviour in multiple sites in England in 2004.

M Hickman1, V Hope, T Brady, P Madden, S Jones, S Honor, G Holloway, F Ncube, J Parry.   

Abstract

We sought to corroborate geographical differences in hepatitis C virus (HCV) prevalence and assess whether these can be explained by differences in injecting risk behaviour. A community recruited interview survey of 1058 injecting drug users (IDU) - including a blood spot specimen for antibody testing - was undertaken in seven cities in England. HCV prevalence varied from 27% to 74% across sites (chi(2)(6) = 115.3, P < 0.001). There was a significant variation in crack-injection, prison history, injecting frequency, homelessness, groin injecting, syringe reuse and sharing between the sites. Adjustment for clustering by site and other covariates attenuated the odds ratios (OR) for most variables: e.g. crack injection changed from an unadjusted OR of >2 to an adjusted OR of 1.4 (95% CI 0.9-2.0). Remaining significant covariates included: homelessness (OR 2.2; 1.4-3.6); ever imprisonment (OR 1.7; 1.2-2.5); syringe sharing >18 months ago (OR 2.0; 1.3-3.0); injecting duration and age. Introducing site as a second level variable did not reach significance (P = 0.10). HCV prevalence among IDU reporting 'never sharing' was 48%. Geographical variation in HCV prevalence remains poorly explained, but should be the key focus of our surveillance effort. Measures of sharing and their interpretation require greater scrutiny.

Entities:  

Mesh:

Year:  2007        PMID: 17697017     DOI: 10.1111/j.1365-2893.2007.00855.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  25 in total

1.  Drug use and phylogenetic clustering of hepatitis C virus infection among people who use drugs in Vancouver, Canada: A latent class analysis approach.

Authors:  B Jacka; B C Bray; T L Applegate; B D L Marshall; V D Lima; K Hayashi; K DeBeck; J Raghwani; P R Harrigan; M Krajden; J S G Montaner; J Grebely
Journal:  J Viral Hepat       Date:  2017-09-04       Impact factor: 3.728

2.  Housing instability among people who inject drugs: results from the Australian needle and syringe program survey.

Authors:  Libby Topp; Jenny Iversen; Eileen Baldry; Lisa Maher
Journal:  J Urban Health       Date:  2013-08       Impact factor: 3.671

3.  Injection drug use and HIV antiretroviral therapy discontinuation in a Canadian setting.

Authors:  Dan Werb; M-J Milloy; Thomas Kerr; Ruth Zhang; Julio Montaner; Evan Wood
Journal:  AIDS Behav       Date:  2013-01

4.  Latent classes of heroin and cocaine users predict unique HIV/HCV risk factors.

Authors:  P T Harrell; B E Mancha; H Petras; R C Trenz; W W Latimer
Journal:  Drug Alcohol Depend       Date:  2011-10-24       Impact factor: 4.492

5.  Sex Discrepancies in the Protective Effect of Opioid Agonist Therapy on Incident Hepatitis C Infection.

Authors:  Louise Geddes; Jenny Iversen; Handan Wand; Aryan Esmaeili; Judith Tsui; Margaret Hellard; Gregory Dore; Jason Grebely; Paul Dietze; Julie Bruneau; Maria Prins; Megan D Morris; Naglaa H Shoukry; Andrew R Lloyd; Arthur Y Kim; Georg Lauer; Andrea L Cox; Kimberly Page; Lisa Maher
Journal:  Clin Infect Dis       Date:  2020-01-01       Impact factor: 9.079

6.  Prevalence of HIV, hepatitis B and hepatitis C and associated risk behaviours amongst injecting drug users in three Afghan cities.

Authors:  Abdul Nasir; Catherine S Todd; M Raza Stanekzai; Christian T Bautista; Boulos A Botros; Paul T Scott; Steffanie A Strathdee; Jeffrey Tjaden
Journal:  Int J Drug Policy       Date:  2010-12-10

Review 7.  Epidemiology of hepatitis C in Croatia in the European context.

Authors:  Tatjana Vilibic-Cavlek; Jasmina Kucinar; Bernard Kaic; Maja Vilibic; Nenad Pandak; Ljubo Barbic; Vladimir Stevanovic; Jasmina Vranes
Journal:  World J Gastroenterol       Date:  2015-08-28       Impact factor: 5.742

8.  Prevalence of hepatitis C virus in young people who inject drugs in four Colombian cities: A cross-sectional study using Respondent Driven Sampling.

Authors:  David Toro-Tobón; Dedsy Berbesi-Fernandez; Pedro Mateu-Gelabert; Ángela M Segura-Cardona; Liliana P Montoya-Vélez
Journal:  Int J Drug Policy       Date:  2018-08-11

Review 9.  High hepatitis C virus prevalence among drug users in Iran: systematic review and meta-analysis of epidemiological evidence (2001-2012).

Authors:  Mohsen Malekinejad; Soodabeh Navadeh; Ali Lotfizadeh; Afarin Rahimi-Movaghar; Masoumeh Amin-Esmaeili; Alireza Noroozi
Journal:  Int J Infect Dis       Date:  2015-10-13       Impact factor: 3.623

Review 10.  Public health and international drug policy.

Authors:  Joanne Csete; Adeeba Kamarulzaman; Michel Kazatchkine; Frederick Altice; Marek Balicki; Julia Buxton; Javier Cepeda; Megan Comfort; Eric Goosby; João Goulão; Carl Hart; Thomas Kerr; Alejandro Madrazo Lajous; Stephen Lewis; Natasha Martin; Daniel Mejía; Adriana Camacho; David Mathieson; Isidore Obot; Adeolu Ogunrombi; Susan Sherman; Jack Stone; Nandini Vallath; Peter Vickerman; Tomáš Zábranský; Chris Beyrer
Journal:  Lancet       Date:  2016-03-24       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.